drugset / Trial / NCT03332225

A Trial of Validation and Restoration of Immune Dysfunction in Severe Infections and Sepsis

NCT03332225

Phase 2 Completed 36 enrolled Hellenic Institute for the Study of Sepsis
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of the study is to conduct one RCT of personalized immunotherapy in sepsis targeting patients who lie either on the predominantly hyper-inflammatory arm or on the predominantly hypo-inflammatory arm of the spectrum of the host response. These patients will be selected by the use of a panel of biomarkers and laboratory findings and they will be randomly allocated to placebo or immunotherapy treatment according to their needs.

Timeline

Start
2017-12-15
Primary completion
2019-12-31
Completion
2019-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Anakinra Protein / enzyme biologic 200 mg Intravenous
Subject Recombinant human interferon-gamma Protein / enzyme biologic Subcutaneous